Anticoagulation monitoring, reimagined

Real-time INR monitoring.
Without the lab.
Without the delay.

A new generation of anticoagulation monitoring — designed for continuous insight, better outcomes, and real patient freedom.

Get in touch Learn about our approach
3–5M
VKA patients in the US and EU requiring regular INR monitoring — the direct addressable market
US: ~2M warfarin users (J. General Internal Medicine, 2024) · EU: Rotterdam Study (European Heart Journal, 2013)
<5%
currently using self-testing, despite clinical guidelines recommending it for eligible patients
Journal of General Internal Medicine, 2024
$57B
projected global anticoagulation therapy market by 2031, growing at 8.4% annually
Data Bridge Market Research, 2023
The problem

Anticoagulation monitoring is outdated.

Anticoagulation is one of the most common long-term therapies in the world — yet its management is stuck in a model built for the 1980s. Patients receive only intermittent snapshots of their INR status, leaving them blind between tests. Continuous, real-time INR monitoring has never existed. Until now.

01

A black box between measurements

Between two measurements, patients have no insight into what their INR is doing. Diet, medication and stress influence blood clotting daily — but those changes remain invisible until the next test.

02

A system built around scarcity

Each INR measurement requires clinical infrastructure: a lab, a technician, a follow-up call. For hospitals and insurers managing thousands of patients, this is an enormous and avoidable ongoing cost.

03

The wrong solution for an aging world

The average VKA patient is elderly, often managing multiple conditions and guided by the thrombosis service. Regular clinic visits are not just inconvenient — for many, they are genuinely difficult. As populations age, the burden will only grow.

Our vision & mission
Vision

A world where monitoring your INR is as natural as checking your heart rate. Continuous, reliable and in the hands of the patient.

Mission

We are building the first solution for continuous INR monitoring — replacing periodic tests with real-time insights that give patients and care providers back control.

Why now
Four forces making this the right moment.

At-home diagnostics

Consumer demand for convenient, accessible health monitoring is accelerating — from glucose patches to cardiac monitors. INR is next.

Sensor innovation

New developments in bioelectronics and optical sensing technology are opening the door to continuous coagulation monitoring for the first time. YNR was founded to seize that opening — and realise that breakthrough.

Patient-centred care

Healthcare systems are shifting toward continuous patient engagement — driven by growing pressure from insurers to make care more efficient and measurable.

An underserved market

Millions of anticoagulation patients lack access to modern monitoring. Self-testing uptake remains far below clinical guideline recommendations.

Our plans for 2026
Building the foundations.
Feasibility validation

Before we build, we need to understand whether it is possible. We are investigating the technical and clinical feasibility of continuous INR monitoring — by testing existing science, consulting experts, and challenging our early assumptions.

Market & ecosystem analysis

Mapping the full anticoagulation monitoring landscape: competitive devices, regulatory pathways (CE Mark / FDA), clinical workflows, and patient behaviour.

Expert engagement

Building a network of advisors across sensing technology, haematology, medical device regulation, and digital health — in close collaboration with clinicians.

Technical partnerships

Exploring partnerships with technical universities and advanced sensing companies to validate optical and electrochemical approaches to continuous coagulation monitoring.

Product development

Our first milestone is a working prototype demonstrating the core sensing approach — built for proof of concept and clinical validation, not the consumer market.

Founder-led, impact-driven
Bas van Zandvoort
Bas van Zandvoort
Founder, YNR

Bas van Zandvoort spent five years at the commercial edge of European tech — scaling revenue and growth at Meltwater and Mollie before that felt like enough. A history degree and time at the Dutch Ministry of Foreign Affairs shaped a way of thinking built on understanding how complex systems, institutions, and people interact. But the founding moment for YNR was personal: heart surgery, and the weeks that followed navigating an anticoagulation monitoring system that was slow, fragmented, and unchanged for decades. For the millions of patients living with that same uncertainty, he believes the solution is long overdue. YNR is how he intends to build it.

Y N R

INR stands for International Normalized Ratio — the clinical measure of how quickly your blood clots. We replaced the “I” with “Y” — for you. Because the goal of YNR is to put that number where it belongs: in the hands of the patient.

Build the next generation of INR monitoring with us.

We are looking for investors who believe early in founders with a mission, technical and academic partners in sensor technology, and clinical collaborators who want to help build the future of anticoagulation monitoring together.

Get in touch Learn more about our approach